GLP1R and urogenital neoplasm: Katagiri and others have also revealed that the effect of DPP-4 inhibitor was mediated by glucagon-like peptide-1 (GLP-1) [4], suggesting that any medicines which increase the level of GLP-1 could prevent cisplatin-induced kidney injury.